SSRI + atypical antipsychotic combination

This page covers all SSRI + atypical antipsychotic combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor, Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole), Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor.

Targets

Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor · Voltage-gated sodium channels (lamotrigine); dopamine D2/D3 receptors (aripiprazole) · Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor · Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor · Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor · Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT1A receptor · Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone) · Dopamine D2 receptor, Serotonin 5-HT2A receptor · Dopamine D2 receptor, serotonin 5-HT2A receptor · Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT2A receptor

Marketed (10)

• Fluoxetine+Olanzapine · University Health Network, Toronto · Psychiatry
  Fluoxetine inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, combining antidepressant and antipsychotic effects.
• Lamotrigine + Aripiprazole · Otsuka Pharmaceutical Development & Commercialization, Inc. · Psychiatry/Neurology
  Lamotrigine stabilizes neuronal membranes by blocking sodium channels, while aripiprazole acts as a dopamine D2/D3 receptor partial agonist, together modulating neurotransmission to treat mood and psychotic disorders.
• Methylphenidate, aripiprazole, and combination · Tri-Service General Hospital · Psychiatry / Neurology
  This combination uses methylphenidate to increase dopamine and norepinephrine activity, while aripiprazole acts as a dopamine partial agonist to modulate psychotic symptoms and mood.
• venlafaxine XR plus aripiprazole · University of Pittsburgh · Psychiatry / Mental Health
  Venlafaxine XR inhibits serotonin and norepinephrine reuptake while aripiprazole acts as a dopamine D2 receptor partial agonist, together addressing both depressive and psychotic symptoms.
• Aripiprazole; Quetiapine · Taichung Veterans General Hospital · Psychiatry/Neurology
  This is a combination of two atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
• Escitalopram+Aripiprazole · Ministry of Health & Welfare, Korea · Psychiatry / Mental Health
  This combination increases serotonin availability in the brain while blocking dopamine receptors to treat depression and related psychiatric conditions.
• Lithium carbonate + perospirone hydrochloride · Shanghai Mental Health Center · Psychiatry
  Lithium carbonate modulates intracellular signaling pathways to stabilize mood, while perospirone hydrochloride acts as an atypical antipsychotic by blocking dopamine and serotonin receptors.
• Olanzapine and Amisulpride · Heinrich-Heine University, Duesseldorf · Psychiatry
  This is a combination of two atypical antipsychotics that block dopamine and serotonin receptors to reduce psychotic symptoms and stabilize mood.
• Risperidone and Zotepine for delirium · Changhua Christian Hospital · Psychiatry / Neurology
  Risperidone and zotepine are atypical antipsychotics that block dopamine D2 and serotonin 5-HT2A receptors to reduce agitation, hallucinations, and delirium symptoms.
• Sertraline + Olanzapine · Weill Medical College of Cornell University · Psychiatry
  Sertraline inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, together providing antidepressant and antipsychotic effects.

Phase 3 pipeline (4)

• Megestrol Acetate and olanzapine · Qingdao Central Hospital · Oncology / Palliative Care / Cachexia
  This combination uses megestrol acetate (a progestin) to stimulate appetite and promote weight gain, while olanzapine (an atypical antipsychotic) provides additional appetite stimulation and may address underlying psychiatric or behavioral symptoms.
• Antidepressant + Aripiprazole · Bristol-Myers Squibb · Psychiatry/Mental Health
  This combination enhances serotonergic and noradrenergic neurotransmission via antidepressant action while aripiprazole provides dopaminergic stabilization and augmentation of antidepressant efficacy.
• ER OROS paliperidone and Olanzapine · Xian-Janssen Pharmaceutical Ltd. · Psychiatry / Neurology
  This combination of an extended-release atypical antipsychotic (paliperidone) and another atypical antipsychotic (olanzapine) works by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.
• Aprepitant plus Olanzapine · Rush University Medical Center · Oncology
  Aprepitant blocks substance P neurokinin-1 receptors while olanzapine antagonizes dopamine and serotonin receptors, together providing enhanced antiemetic and anti-nausea effects.

Patent intelligence

• atypical antipsychotic combination patent landscape — aggregated cliff calendar, attackable patents, originator estates